The large capillarity of the RDSL is also a key part of IDOR’s research in the field of hematology since the substantial volume of patients makes it possible, for example, to carry out research into uncommon diseases and to develop studies that require large amounts of data.

In this sense, the hematology team develops studies with real-world data, which use artificial intelligence to analyze the outcomes of thousands of patients and translate the results into scientific progress and improved healthcare. Work with this focus helps to understand the behavior of drugs beyond controlled clinical trials based on observations from daily hospital routines in situations that deviate from protocols.

In addition to clinical trials with new molecules, IDOR has established itself as a reference center in cell therapy research having participated in clinical trials with innovative therapies such as CarT-Cell for lymphomas resistant to currently available treatments. In this new therapeutic proposal, patients are treated with their own cells – more specifically, T lymphocytes – which are collected and genetically modified to express receptors that recognize and attack tumor cells. The expertise acquired in clinical trials such as this will enable IDOR to develop other cell therapy proposals in the future.